Harmony Gold Mining Company Limited (HMY) Forms $1.68 Double Bottom; 4 Analysts Bullish PTC Therapeutics, Inc. (PTCT)

December 7, 2017 - By Ellis Scott

Harmony Gold Mining Company Limited (HMY) formed double bottom with $1.52 target or 9.00% below today’s $1.68 share price. Harmony Gold Mining Company Limited (HMY) has $738.10M valuation. The stock increased 0.30% or $0.005 during the last trading session, reaching $1.675. About 450,431 shares traded. Harmony Gold Mining Company Limited (NYSE:HMY) has declined 31.33% since December 7, 2016 and is downtrending. It has underperformed by 48.03% the S&P500.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 34 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, November 11 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Underweight” rating by JP Morgan on Monday, October 9. The firm earned “Outperform” rating on Friday, October 16 by Oppenheimer. Citigroup downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, February 24 to “Neutral” rating. The firm earned “Outperform” rating on Thursday, February 25 by Oppenheimer. J.P. Morgan downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday, October 9 to “Sell” rating. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, August 9 with “Hold” rating. RBC Capital Markets maintained it with “Outperform” rating and $85 target in Friday, July 31 report. The stock has “Neutral” rating by Credit Suisse on Tuesday, July 26. The stock has “Sector Perform” rating by RBC Capital Markets on Wednesday, February 24. See PTC Therapeutics, Inc. (NASDAQ:PTCT) latest ratings:

16/11/2017 Broker: J.P. Morgan Rating: Hold New Target: $15.0 Upgrade
16/11/2017 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
26/10/2017 Broker: Bank of America Rating: Sell New Target: $14.0 Downgrade
25/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $15.0 Maintain
09/10/2017 Broker: J.P. Morgan Rating: Sell Downgrade
09/10/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
29/09/2017 Broker: Barclays Capital Rating: Hold New Target: $15.0
26/09/2017 Broker: J.P. Morgan Rating: Hold Maintain
26/09/2017 Broker: Credit Suisse Rating: Buy New Target: $25.0
14/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $15.0 Maintain

Among 7 analysts covering Harmony Gold Mining (NYSE:HMY), 0 have Buy rating, 1 Sell and 6 Hold. Therefore 0 are positive. Harmony Gold Mining had 12 analyst reports since August 20, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, July 1 by Macquarie Research. Macquarie Research downgraded Harmony Gold Mining Company Limited (NYSE:HMY) on Tuesday, March 15 to “Underperform” rating. The rating was downgraded by Bank of America to “Neutral” on Friday, October 20. The firm has “Hold” rating given on Thursday, August 20 by Zacks. The rating was downgraded by Deutsche Bank on Friday, March 17 to “Sell”. The company was downgraded on Friday, November 11 by Citigroup. The company was upgraded on Friday, November 11 by Morgan Stanley. On Friday, November 11 the stock rating was downgraded by HSBC to “Hold”. JP Morgan downgraded the shares of HMY in report on Monday, September 14 to “Neutral” rating. The company was upgraded on Thursday, November 30 by Deutsche Bank.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $681.67 million. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

The stock increased 1.99% or $0.32 during the last trading session, reaching $16.43. About 90,922 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since December 7, 2016 and is uptrending. It has outperformed by 87.81% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com